S. Hata Yujiro's Insider Trades & SAST Disclosures
S. Hata Yujiro's most recent trade in Enanta Pharmaceuticals Inc was a trade of 15,700 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern S. Hata Yujiro.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.52 per share. | 18 Feb 2025 | 12,808 | 690,695 (3%) | 0% | 19.5 | 250,012 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 12,808 | 182,192 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 83,856 | 83,887 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 83,856 | 761,743 (3%) | 0% | 4.3 | 361,419 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 56,711 | 734,598 (3%) | 0% | 4.3 | 244,424 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 56,711 | 167,743 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.60 per share. | 14 May 2024 | 54,408 | 680,190 (3%) | 0% | 41.6 | 2,263,433 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.57 per share. | 14 May 2024 | 53,592 | 708,151 (3%) | 0% | 42.6 | 2,281,631 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 34,433 | 49,454 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 34,433 | 712,320 (3%) | 0% | 4.3 | 148,406 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.73 per share. | 14 May 2024 | 30,084 | 682,236 (3%) | 0% | 41.7 | 1,255,505 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 43.48 per share. | 14 May 2024 | 29,761 | 678,390 (3%) | 0% | 43.5 | 1,293,934 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.37 per share. | 14 May 2024 | 4,349 | 677,887 (3%) | 0% | 42.4 | 184,250 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.84 per share. | 14 May 2024 | 2,303 | 677,887 (3%) | 0% | 41.8 | 96,348 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.12 per share. | 14 May 2024 | 503 | 677,887 (3%) | 0% | 44.1 | 22,191 | Common Stock |
| Enanta Pharmaceuticals Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 480,000 | 480,000 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | S. Yujiro Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 08 Feb 2024 | 75,815 | 753,702 (3%) | 0% | 4.3 | 326,763 | Common Stock |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.15 per share. | 08 Feb 2024 | 75,815 | 677,887 (3%) | 0% | 45.1 | 3,422,835 | Common Stock |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 75,815 | 248,011 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.54 per share. | 08 Feb 2024 | 23,557 | 677,887 (3%) | 0% | 45.5 | 1,072,715 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 08 Feb 2024 | 23,557 | 701,444 (3%) | 0% | 4.3 | 101,531 | Common Stock |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 23,557 | 224,454 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Hata Yujiro S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 628 | 323,826 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Hata S. Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 01 Feb 2024 | 628 | 678,515 (3%) | 0% | 4.3 | 2,707 | Common Stock |
| Ideaya Biosciences Inc | Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 01 Feb 2024 | 624 | 677,891 (3%) | 0% | 45 | 28,080 | Common Stock |
| Ideaya Biosciences Inc | Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 01 Feb 2024 | 4 | 677,887 (3%) | 0% | 45 | 180 | Common Stock |
| Ideaya Biosciences Inc | S. Hata Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2024 | 62,739 | 324,454 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.17 per share. | 12 Jan 2024 | 62,739 | 677,887 (3%) | 0% | 40.2 | 2,519,968 | Common Stock |
| Ideaya Biosciences Inc | S. Hata Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Jan 2024 | 62,739 | 740,626 (3%) | 0% | 4.3 | 270,405 | Common Stock |
| Ideaya Biosciences Inc | Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 12 Jan 2024 | 12,261 | 677,887 (3%) | 0% | 40.0 | 490,913 | Common Stock |
| Ideaya Biosciences Inc | S. Yujiro Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2024 | 12,261 | 387,193 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Jan 2024 | 12,261 | 690,148 (3%) | 0% | 4.3 | 52,845 | Common Stock |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 15 Dec 2023 | 75,000 | 677,887 (3%) | 0% | 35.0 | 2,627,618 | Common Stock |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 75,000 | 399,454 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 15 Dec 2023 | 75,000 | 752,887 (3%) | 0% | 4.3 | 323,250 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2023 | 11,601 | 474,454 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Apr 2023 | 11,601 | 677,887 (3%) | 0% | 4.3 | 50,000 | Common Stock |
| Enanta Pharmaceuticals Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Xencor Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 21,412 | 21,412 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2021 | 13,144 | 13,144 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 195,000 | 195,000 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 22 Dec 2020 | 8,000 | 666,286 (3%) | 0% | 4.3 | 34,480 | Common Stock |
| Ideaya Biosciences Inc | Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 8,000 | 486,055 | - | - | Stock Option (right to buy) | |
| Xencor Inc | Yujiro S. Hata | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 13,953 | 13,953 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges